“This patent, the first ever issued to FTI, represents a significant broadening of our intellectual property coverage and affirms our company’s leading position in the commercialization of this important technology” said Dr. Philip E. Yeske, President and Chief Executive Officer of Fluorous Technologies.

Fluorous Technologies, Inc. (FTI) is a chemical technology company dedicated to the development and commercialization of fluorous products focused at the life science market. The company uses patented technology to solve synthesis and separation problems spanning the entire drug discovery and development process. FTI further leverages its enabling technology through service contracts, licenses, and collaborations.

“This research was funded by an SBIR Phase II grant from the NIH. In our research, we targeted to develop new processes utilizing microwave and F-SPE techniques to extend the chemical development of Professor Dennis Curran for fluorous mixture synthesis of discovery libraries of novel drug-like structures,” said Dr. Wei Zhang, Director of Discovery Chemistry for Fluorous Technologies.

Fluorous Technologies, Inc. (FTI) is a chemical technology company dedicated to the development and commercialization of fluorous products focused at the life science market. The company uses patented technology to solve synthesis and separation problems spanning the entire drug discovery and development process. FTI further leverages its enabling technology through service contracts, licenses, and collaborations.

“Yimin joined FTI in 2003 from the pharmaceutical industry, bringing with him good medicinal chemistry experience to our Discovery Chemistry Group. The unique environment of FTI as a start-up company had provided ample opportunities for him to develop many aspects of his talents. He has made contributions to the development of new fluorous reagents, separation techniques and library synthesis as well,” said Dr. Wei Zhang, Director of Discovery Chemistry for Fluorous Technologies.

Fluorous Technologies, Inc. (FTI) is a chemical technology company dedicated to the development and commercialization of fluorous products focused at the life science market. The company uses patented technology to solve synthesis and separation problems spanning the entire drug discovery and development process. FTI further leverages its enabling technology through service contracts, licenses, and collaborations.

Fluorous Technologies, Inc. (FTI) announces the launch of a new line of products for use in proteomics. The five new products tag a diverse group of peptides and proteins, and are based on the seminal work on fluorous proteomics conducted at the Genomics Institute of the Novartis Research
Foundation (GNF). As recently reported in Nature Biotechnology, GNF has adapted fluorous chemistry methods for use in the simple isolation of proteins and peptides based on fluorous affinity chromatography.

Proteomics, which is the study of proteins and their role in biological systems, begins with analysis of naturally occurring proteins. Proteomics aims to determine which proteins, and in what quantities, are present in both healthy and abnormal states, with the ultimate goal of finding new therapies and diagnostic tools for diseases. A deep understanding of the human proteome as it relates to disease is seen as the next major challenge that the life sciences industry faces since the completion of the Human Genome Project.   Anumber of technologies for separating, identifying, and counting proteins have been developed. However, existing solutions can be expensive and their ability to isolate rare proteins is limited.

Fluorous chemistry is a widely-adaptable, fast, and selective separation technology. Fluorous compounds contain a highly fluorinated region that serves as a molecular affinity tag, enabling simple manipulation and isolation from chemical and biological mixtures. Fluorous tags can be applied to a wide range of organic compounds, including small molecules, peptides, proteins, and oligonucleotides. The technology is also compatible with traditional synthesis and bioprocessing strategies.

“This is a whole new generation of affinity tagging technology,” said Dr. Marvin Yu, Director of Chemistry at FTI. “Not only is fluorous chemistry remarkably selective, but it promises to be more cost effective than the widely used biotin-streptavidin system.” In addition, the unique properties of fluorous affinity have allowed the GNF researchers to develop new analytical techniques, like differentiating among similarly functionalized peptides based on the number of tags applied. “Multiplexing is an important aspect of proteomics research,” Dr. Yu continued, “and fluorous chemistry offers all the attributes necessary to be successful in this mode.”

“This groundbreaking work on fluorous proteomics is further evidence of the broadly enabling nature of our foundation technology,” said Dr. Philip E. Yeske, CEO of Fluorous Technologies. “We are pleased to expand our fluorous chemistry expertise and product offering into this important field.”

FTI intends to provide additional products and kits to the proteomics marketplace as technology development continues.

About Fluorous Technologies, Inc.
FTI offers advanced separation chemistry technology for use in life sciences. Applications of FTI’s molecular affinity tags range from  separations and scavenging in medicinal chemistry, to purification of synthetic peptides and oligonucleotides, to protein enrichment in proteomics. For more information, please visit www.fluorous.com.

Berry & Associates, Inc. and Fluorous Technologies, Inc. (FTI) announce the signing of a licensing agreement that brings fluorous separation technology to oligonucleotide synthesis. Berry & Associates launched a line of fluorous-adapted oligonucleotide synthesis products based on the agreement, which provides Berry & Associates and its customers with access to FTI’s proprietary fluorous synthesis and separation technology.

Oligonucleotides, which are small synthetic fragments of the nucleic acids DNA and RNA, are used in biomedical research, therapeutics, and for the detection of genetic mutations. Laboratory synthesis of oligonucleotides has been essential to the molecular biology revolution; however, purification challenges have historically limited the yield, purity and length of oligonucleotides.

Fluorous chemistry is a widely-adaptable, fast, and selective separation technology. New to science in the past decade, fluorous affinity tags act as molecular handles for purification without affecting any other aspect of the chemistry. After placing a fluorous tag on an oligonucleotide by means of traditional solid-phase techniques, the tagged material can be easily separated from impurities. The tag is then removed, leaving the pure product.

“Berry & Associates has extended Fluorous Technologies’ foundation technology to oligonucleotide synthesis,” said Dr. William H. Pearson, the Vice President for Research and Development at Berry & Associates. “Our new fluorous affinity purification products allow researchers to quickly isolate higher yields of oligonucleotides than is possible by other means, especially when long oligonucleotides are required. We believe this has great implications for oligonucleotide applications in disease research, diagnosis, and treatment.”

“We congratulate Berry & Associates on the launch of these products and look forward to working closely with them to support the synthetic oligonucleotide market,” said Dr. Philip E. Yeske, CEO of Fluorous Technologies. “This compelling new application is further evidence of the remarkable range of chemistries that can be enhanced via fluorous techniques. Oligonucleotides, together with peptides, proteins, and oligosaccharides, are an important class of compounds in the life sciences, and they expand our company’s core applications in drug discovery to include the purification of natural and synthetic biomolecules.”

About Fluorous Technologies, Inc.
FTI offers advanced separation chemistry technology for use in life sciences. Applications of FTI’s molecular affinity tags range from separations and scavenging in medicinal chemistry, to purification of peptides and other biomolecules, to protein enrichment in proteomics. For more information, please visit www.fluorous.com.

About Berry & Associates, Inc.
Berry & Associates, Inc., located in Dexter, MI, is a privately held chemistry-based biotechnology company founded in 1989 that provides biomedical researchers with DNA and RNA building blocks, fluorescent markers, and other molecular tools. More information can be found at www.berryassoc.com.

Pittsburgh, PA – Fluorous Technologies, Inc. (FTI) and Sigma-Aldrich (Nasdaq: SIAL) announce the availability of FTI products from Sigma-Aldrich. Fluorous chemicals and sorbent products can now be purchased using the 2005/2006 Fluka Catalogue or 2005/2006 Aldrich Handbook and at sigma-aldrich.com.

“We are very pleased to have Sigma-Aldrich as our distribution partner. Their reputation for technical expertise, quality, and customer service, not to mention the fact that nearly every laboratory in the world has their catalogues, creates a strong link between customers and our advanced separation chemistry products,” said Dr. Philip Yeske, CEO of Fluorous Technologies, Inc. “While FTI will also continue to sell its products directly, availability of fluorous compounds under the Fluka brand will be a great sourcing option for many chemists.”

“Fluorous chemistry improves productivity through efficient purification,” said Dr. Hans-Jürgen Kohlbau, Product Manager Organics at Sigma-Aldrich. “We are excited to offer our customers a broad range of novel products for this unique technology showing great promise in both green chemical process development and the entire drug discovery and development process.”

Fluorous products are novel chemical and sorbent tools that facilitate the synthesis and separation of organic molecules and biopolymers during library generation in drug discovery research. They enable an easy, scaleable work-up of reaction mixtures and the recovery and recycling of expensive catalytic species.

Fluorous methods are attractive and easy to apply because the experimental techniques (solution phase reactions, liquid-liquid extractions, solid phase extractions) are familiar to practicing organic chemists. In addition to being compatible with a wide variety of chemical reactions, fluorous chemistry is also compatible with several new synthesis technologies, like automated high throughput parallel synthesis, the use of supercritical CO2, and microwave synthesis.

Fluorous synthesis and separation is the subject of a ChemFiles newsletter from Sigma Aldrich, which is widely respected as a resource for products and technical information associated with important new technologies. The upcoming issue, Vol 4 No 9, displays Sigma-Aldrich’s entire line of products for fluorous synthesis and separation.

Fluorous systems are nearly as straightforward as resins, offering a general, robust, selective, and orthogonal separation method to isolate products from reaction mixtures. Unlike resins, however, fluorous chemistry also features the kinetic efficiency of solution-phase, the ability to do in-process analytical monitoring, and access to the full lexicon of familiar solution-phase reactions.

A wide range of solution-phase organic reactions can be adapted to exploit fluorous advantages without change to the synthetic strategy. As a true homogeneous support, fluorous tags can even be used in transformations that are not accessible when using solid-phase approaches.

About Fluorous Technologies: FTI is a chemical technology company that develops fluorous products and applications for use in life science and materials applications. FTI is the world’s only company dedicated to commercializing this important new chemistry. Applications of FTI’s products range from molecular affinity tags and homogeneous scavengers in medicinal chemistry, to purification of peptides and oligos, to protein enrichment in quantitative proteomics. The Company’s technology also enhances both automated and microwave chemistries. FTI was founded in 2000 by Prof. Dennis P. Curran – a recognized pioneer in the field and holder of seminal patents on fluorous compositions and applications. For more information, please visit www.fluorous.com.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 34 countries and has over 6,000 employees providing excellent service worldwide. The Company is committed to the success of its Customers, Employees and Shareholders through leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning web site at sigma-aldrich.com.

This release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs and other statements regarding the Company’s expectations, goals, beliefs, intentions and the like, which involve assumptions regarding Company operations and conditions in the markets the Company serves. The Company does not undertake any obligation to update these forward-looking statements.

FTI also received a Phase II SBIR grant entitled “Rapid Fluorous Synthesis of Drug-like Small Molecules”. The project’s objective is to expand FTI’s broad-based technology platform with new fluorous chemicals and techniques for the modern drug discovery environment, with emphasis on practical solutions that speed up the synthesis and separation process. The centerpiece of this important grant will be the development of a rapid fluorous synthesis toolkit for drug discovery chemists.

“Beyond the generous financial support of NIH, these awards are important validation of the scientific and commercial value of fluorous chemistry,” said Dr. Philip E. Yeske, FTI’s President and CEO. “They also illustrate the remarkable scope of chemistry applications that can be enhanced with fluorous technology.”

Fluorous Technologies, Inc. (FTI) is a chemical technology company dedicated to the development and commercialization of fluorous products for the life science market. The company uses its patented technology to solve synthesis and separation problems spanning the entire drug discovery and development process. Fluorous chemistry enhances a wide range of applications, including medicinal chemistry, combinatorial chemistry, catalysis, peptide and oligonucleotide production, and proteomics. For more information please visit
www.fluorous.com

Fluorous Technologies Inc. (FTI) has exclusively licensed two new patents from the University of Pittsburgh. The addition of U.S. Patents 6727390 (Fluorous Phosphines and Phosphine Oxides) and 6734318 (Fluorous Triphase and Other Multiphase Systems) further extends FTI’s intellectual property umbrella, which covers nearly every aspect of commercially-practical fluorous synthesis and separation.

USP6727390, issued in April 2004, identifies a family of new fluorous phosphine compounds, which have numerous uses in pharmaceutical synthesis. These compounds are already among FTI’s top-selling products. USP6734318,
issued in May 2004, describes the fundamental concept of using fluorous phase-partitioned liquid systems for
chemical separations. In addition to having promise as a new approach to pharmaceutical purification at all
scales, this innovative technology is the basis for a major SBIR grant awarded by the National Institutes of Health to FTI.

“Every drug-discovery chemist is familiar with phosphines. Like other fluorous reagents, the new fluorous phosphines work just the same as their conventional counterparts, but they also make the tedious separation chemistry simple,” said Dr. Philip E. Yeske, FTI’s President & CEO.

“Triphasic separation is a groundbreaking new technique that leverages the powerful orthogonality of the fluorous phase,” added Dr. Marvin S. Yu, FTI’s Director of Process Chemistry. “We see this as potentially the most important advancement in process chemical separation systems since the development of simulated moving-bed chromatography.”

Fluorous Technologies, Inc. (FTI) is a chemical technology company dedicated to the development and commercialization of fluorous products for the life science market. The company uses its patented technology to solve synthesis and separation problems spanning the entire drug discovery and development process. Fluorous chemistry enhances a wide range of applications, including medicinal chemistry, combinatorial chemistry, catalysis, peptide and oligonucleotide production, and proteomics. For more information please visit
www.fluorous.com

Fluorous technologies using fluorous phase tags combined with unique fluorous separation methods have become a powerful tool for solution-phase parallel and combinatorial syntheses. In a special issue of Chemical Reviews on Heterocycles published in May 2004, Dr. Wei Zhang, Director of Discovery Chemistry at FTI, published an article entitled “Fluorous Synthesis of Heterocyclic Systems” 2004, 104, 2531-2556).

This article includes over one hundred references summarizing the recent progress of heterocyclic synthesis using fluorous reagents, catalysts, scavengers, protecting groups, and tags. The paper also serves as a comprehensive general review of the current state of fluorous techniques in organic synthesis and separation, with discussion of fluorous-enhanced multicomponent reactions, microwave reactions, triphasic reactions, solid-phase synthesis of peptides and oligosaccharides, and mixture synthesis of natural products.

Fluorous Technologies, Inc. (FTI) is a chemical technology company dedicated to the development and commercialization of fluorous products for the life science market. The company uses its patented technology to solve synthesis and separation problems spanning the entire drug discovery and development process. Fluorous chemistry enhances a wide range of applications, including medicinal chemistry, combinatorial chemistry, catalysis, peptide and oligonucleotide production, and proteomics. For more information please visit www.fluorous.com

“Fluorous mixture synthesis is a new solution-phase approach to the preparation of drug candidate compounds,” said Dr. Philip Yeske, President and CEO of FTI. “Lead optimization in particular should benefit from the combined advantage of mixture synthesis efficiency and fluorous separation simplicity.”

Dr. Wei Zhang, Director of Discovery Chemistry at FTI and Principal Investigator on the grant added, “Phase I research demonstrated the synthesis of natural product mappicine analogs, and Phase II focused on the design and development of small drug-like compound libraries with novel heterocyclic scaffolds.  The combination of fluorous mixture synthesis with multi-component reactions and microwave technologies are additional features of this project.”

FTI is a Pittsburgh-based chemical technology company focused on the life sciences market. FTI’s products combine the flexibility and performance of solution-phase chemistry with facile separations comparable to solid-phase techniques.  Fluorous-enhanced chemistry spans a wide range of applications, including drug discovery, combinatorial chemistry, catalysis, and peptide and oligonucleotide production. For more information, please visit www.fluorous.com.